- Metformin reduces knee pain in overweight or obese patients with osteoarthritis.
- The drug demonstrated good safety and tolerability in the clinical trial.
- Anti-inflammatory and metabolic actions of metformin were suggested to contribute to its potential benefits in addressing the therapeutic gap in osteoarthritis treatment for obese patients.
- The study pointed to the need for future larger clinical trials to confirm the findings and explore metformin's effects on disease progression.
- The limitations included a small sample size, telemedicine-based assessments, and reliance on self-reporting.
Source: JAMA
